Inhibitory effects of lupeal acetate of Cortex periplocae on N-nitrosomethylbenzylamine-induced rat esophageal tumorigenesis

Oncology Letters

Volumn 4, Issue 2, 2012, Pages 231-236

  Wang, Lifang ^a   Lu, An ^b   Meng, Fanru ^a   Cao, Qing ^a   Shan, Baoen ^a  

^a HEBEI MEDICAL UNIVERSITY   (China)

^b Hebei Province Center for Disease Control and Prevention   (China)

Author keywords

catenin; Esophageal tumorigenesis; Lupeal acetate of Cortex periplocae; N nitrosomethylbenzylamine

Indexed keywords

ANTINEOPLASTIC AGENT; BETA CATENIN; GLYCOGEN SYNTHASE KINASE 3BETA; LUPEAL ACETATE; MYC PROTEIN; N BENZYL N METHYLNITROSAMINE; PLANT EXTRACT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARCINOGENESIS; CHEMICAL STRUCTURE; CONTROLLED STUDY; CORTEX PERIPLOCAE; ESOPHAGUS; ESOPHAGUS CARCINOGENESIS; GENE EXPRESSION; MALE; MEDICINAL PLANT; NONHUMAN; ONCOGENE C MYC; PROTEIN EXPRESSION; RAT;

EID: 84861996545     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2012.717     Document Type: Article

References (41)

1. Blot WJ and McLaughlin JK: The changing epidemiology of esophageal cancer. Semin Oncol 26: 2-8, 1999.
2. American Cancer Society: Cancer facts and figures, 2005. Atlanta, GA: American Cancer Society, 2005.
3. Zou XN, Chen WQ, Zhang SW, Li LD, Lu FZ and Chen YH: An analysis of esophageal cancer incidence and mortality from 30 cancer registries in China, 1998-2002. Chin Cancer 161: 142-146, 2007.
4. Stoner GD and Gupta A: Etiology and chemoprevention of esophageal squamous cell carcinoma. Carcinogenesis 22: 1737-1746, 2001.
5. Kakizoe T: Chemoprevention of cancer-focusing on clinical trials. Jpn J Clin Oncol 33: 421-442, 2003.
6. Cragg GM, Grothaus PG and Newman DJ: Impact of natural products on developing new anti-cancer agents. Chem Rev 109: 3012-3043, 2009.
7. Koehn FE and Carter GT: The evolving role of natural products in drug discovery. Nat Rev Drug Discov 4: 206-220, 2005.
8. Mann J: Natural products in cancer chemotherapy: past, present and future. Nat Rev Cancer 2: 143-148, 2002.
9. National Committee of Pharmacopoeia: Pharmacopoeia of the People's Republic of China. Chemical Industry Publishing Company, Beijing, China, pp.181, 2005 (In Chinese).
10. Itokawa H, Xu JP and Takeya K: Studies on chemical constituents of antitumor fraction from Periploca sepium. V. Structures of new pregnane glycosides, periplocosides J, K, F and O. Chem Pharm Bull 36: 4441-4446, 1998.
11. Zhang J, Shan BE and Liu GS: Apoptosis induced by ethyl acetate extract from Cortex periplocae in human breast cancer cell line MCF-7. Tumor 26: 418-421, 2006 (in Chinese).
12. Zhao LM, Shan BE, Ai J, Ren FZ and Lian YS: Effects of periplocin from Cortex periplocae on proliferation of human esophageal carcinoma cells TE-13 and related mechanisms. Tumor 28: 203-206, 2008 (in Chinese).
13. Polakis P: The oncogenic activation of beta-catenin. Curr Opin Genet Dev 9: 15-21, 1999.
14. Waltzer L and Bienz M: The control of beta-catenin and TCF during embryonic development and cancer. Cancer Metastasis Rev 18: 231-246, 1999.
15. Behrens J: Control of beta-catenin signaling in tumor development. Ann NY Acad Sci 910: 21-33, 2000.
16. Lv J, Cao XF, Ji L, Zhu B, Tao L and Wang DD: Association of Wnt1/beta-catenin with clinical pathological characteristics and prognosis of esophageal squamous cell carcinoma. Genet Test Mol Biomarkers 14: 363-369, 2010.
17. Luu HH, Zhang R, Haydon RC, Rayburn E, Kang Q, Si W, Park K, Wang H, Peng Y, Jiang W and He TC: Wnt/beta-catenin signaling pathway as a novel cancer drug target. Curr Cancer Drug Targets 4: 653-671, 2004.
18. Kitagawa M, Hatakeyama S, Shirane M, Matsumoto M, IshidaN, Hattori K, Nakamichi I, Kikuchi A and Nakayama K: An F-box protein, FWD1, mediates ubiquitin-dependent proteolysis of beta-catenin. EMBO J 18: 2401-2410, 1999.
19. Liu C, Li Y, Semenov M, Han C, Baeg GH, Tan Y, Zhang Z, LinX and He X: Control of beta-catenin phosphorylation/degradation by a dual-kinase mechanism. Cell 108: 837-847, 2002.
20. Nelson WJ and Nusse R: Convergence of Wnt, beta-catenin, and cadherin pathways. Science 303: 1483-1487, 2004.
21. Moon RT, Bowerman B, Boutros M and Perrimon N: The promise and perils of Wnt signaling through beta-catenin. Science296: 1644-1646, 2002.
22. Akiyama T: Wnt/beta-catenin signaling. Cytokine Growth Factor Rev 11: 273-282, 2000.
23. Takahashi-Yanaga F and Sasaguri T: Drug development targeting the glycogen synthase kinase-3beta (GSK-3beta)-mediated signal transduction pathway: inhibitors of the Wnt/beta-catenin signaling pathway as novel anticancer drugs. J Pharmacol Sci109: 179-183, 2009.
24. Xiang YY, Wang DY, Tanaka M, Igarashi H, Kamo T, ShenQ, Sugimura H and Kino I: Efficient and specific induction of esophageal tumors in rats by precursors of N-nitrososarcosine ethyl ester. Pathol Int 45: 415-421, 1995.
25. Wang L, Lu A, Liu X, Sang M, Shan B, Meng F, Cao Q and Ji X: The flavonoid Baohuoside-I inhibits cell growth and downregulates survivin and cyclin D1 expression in esophageal carcinoma via β-catenin-dependent signaling. Oncol Rep 26: 1149-1156, 2011.
26. Osterheld MC, Bian YS, Bosman FT, Benhatter J and FontollietC: Beta-catenin expression and its association with prognostic factors in adenocarcinoma developed in Barrett esophagus. Am J Clin Pathol 117: 451-456, 2002.
27. Wu D and Pan W: GSK3: a multifaceted kinase in Wnt signaling. Trends Biochem Sci 35: 161-168, 2010.
28. He TC, Sparks AB, Rago C, Hermeking H, Zawel L, da Costa LT, Morin PJ, Vogelstein B and Kinzler KW: Identification of c-myc as a target of the APC pathway. Science 281: 1509-1512, 1998.
29. Giles RH, van Es JH and Clevers H: Caught up in a Wnt storm: Wnt signaling in cancer. Biochim Biophys Acta 1653: 1-24, 2003.
30. Situ DR, Hu Y, Zhu ZH, Wang J, Long H and Rong TH: Prognostic relevance of β-catenin expression in T2-3N0M0 esophageal squamous cell carcinoma. World J Gastroenterol 16: 5195-5202, 2010.
31. Yang F, Zeng Q, Yu G, Li S and Wang CY: Wnt/beta-catenin signaling inhibits death receptor-mediated apoptosis and promotes invasive growth of HNSCC. Cell Signal 18: 679-687, 2006.
32. Goto M, Mitra RS, Liu M, Lee J, Henson BS, Carey T, Bradford C, Prince M, Wang CY, Fearon ER and D'Silva NJ: Rap1 stabilizes beta-catenin and enhances beta-catenin-dependent transcription and invasion in squamous cell carcinoma of the head and neck. Clin Cancer Res 16: 65-76, 2010.
33. Tsai YP, Yang MH, Huang CH, Chang SY, Chen PM, Liu CJ, TengSC and Wu KJ: Interaction between HSP60 and beta-catenin promotes metastasis. Carcinogenesis 30: 1049-1057, 2009.
34. Morin PJ, Sparks AB, Korinek V, Barker N, Clevers H, VogelsteinB and Kinzler KW: Activation of beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC. Science 275: 1787-1790, 1997.
35. Dilek FH, Topak N, Tokyol C, Akbulut G and Dilek ON: β-Catenin and its relation to VEGF and cyclin D1 expression in pT3 rectosigmoid cancers. Turk J Gastroenterol 21: 365-371, 2010.
36. DasGupta R, Kaykas A, Moon RT and Perrimon N: Functional genomic analysis of the Wnt-wingless signaling pathway. Science308: 826-833, 2005.
37. Saifo MS, Rempinski DR Jr, Rustum YM and Azrak RG: Targeting the oncogenic protein beta-catenin to enhance chemotherapy outcome against solid human cancers. Mol Cancer 9: 310-320, 2010.
38. Paul S and Dey A: Wnt signaling and cancer development: therapeutic implication. Neoplasma 55: 165-176, 2008.
39. Ma C, Wang J, Gao Y, Gao TW, Chen G, Bower KA, Odetallah M, Ding M, Ke Z and Luo J: The role of glycogen synthase kinase 3beta in the transformation of epidermal cells. Cancer Res 67: 7756-7764, 2007.
40. Wang W, Xue L and Wang P: Prognostic value of β-catenin, c-myc, and cyclin D1 expressions in patients with esophageal squamous cell carcinoma. Med Oncol 28: 163-169, 2011.
41. Albihn A, Johnsen JI and Henriksson MA: MYC in oncogenesis and as a target for cancer therapies. Adv Cancer Res 107: 163-224, 2010.